These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8622113)

  • 41. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of isepamicin in vitro efficiency in Gram negative bacteria efficacy of isepamicin.
    Yeliz TC; Ali HB; Sarah AF; Sreylis N; Kubra HU; Asuman B
    Indian J Med Microbiol; 2021 Jan; 39(1):59-62. PubMed ID: 33610258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.
    Fass RJ
    Arch Intern Med; 1980 Jun; 140(6):763-8. PubMed ID: 7387270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of fleroxacin in combination with other antimicrobial agents.
    Neu HC; Chin NX
    Am J Med; 1993 Mar; 94(3A):9S-16S. PubMed ID: 8452190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cefotaxime: microbiology, pharmacology, and clinical use.
    Dudley MN; Barriere SL
    Clin Pharm; 1982; 1(2):114-24. PubMed ID: 6309465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative antimicrobial activities of ribostamycin, gentamicin, ampicillin and lincomycin in vitro and in vivo.
    Inouye S; Watanabe T; Kitasato I
    Drugs Exp Clin Res; 1989; 15(10):465-76. PubMed ID: 2632215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical pharmacokinetics and pharmacodynamics of isepamicin.
    Tod M; Padoin C; Petitjean O
    Clin Pharmacokinet; 2000 Mar; 38(3):205-23. PubMed ID: 10749517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Once-daily versus multiple-daily dosing of aminoglycosides.
    Craig WA
    J Chemother; 1995 Jun; 7 Suppl 2():47-52. PubMed ID: 8622110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India.
    Siddiqui T; Kar M; Dubey A; Patel SS; Sahu C
    J Lab Physicians; 2023 Sep; 15(3):419-424. PubMed ID: 37564217
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro activity of isepamicin (Sch 21420), a new aminoglycoside.
    Qadri SM; Ueno Y; Tullo D; Saldin H
    Chemotherapy; 1995; 41(1):14-7. PubMed ID: 7875017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.
    Over U; Gür D; Unal S; Miller GH;
    Clin Microbiol Infect; 2001 Sep; 7(9):470-8. PubMed ID: 11678929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics.
    Greenhalgh JM; Edwards JR
    Clin Microbiol Infect; 1997 Feb; 3 Suppl 4():S20-S31. PubMed ID: 11869239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate.
    Pien FD; Ho PW
    Am J Hosp Pharm; 1981 Jul; 38(7):981-9. PubMed ID: 7020413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Susceptibility of Gram-negative bacteria to isepamicin: a systematic review.
    Falagas ME; Karageorgopoulos DE; Georgantzi GG; Sun C; Wang R; Rafailidis PI
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):207-18. PubMed ID: 22339194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aminoglycoside resistance. Enzymatic mechanisms in clinical bacterial strains in Slovakia during the last decade.
    Kallová J; Kettner M; Macicková T; Milosovic P; Langsádl L
    FEMS Immunol Med Microbiol; 1997 Sep; 19(1):89-94. PubMed ID: 9322073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dactimicin, a new, less toxic aminoglycoside antibiotic active against resistant bacteria.
    Omoto S; Yoshida T; Kurebe M; Inouye S
    Drugs Exp Clin Res; 1987; 13(12):719-25. PubMed ID: 3447874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents.
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Dec; 23(4):157-60. PubMed ID: 9407222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece.
    Maraki S; Samonis G; Karageorgopoulos DE; Mavros MN; Kofteridis D; Falagas ME
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3067-73. PubMed ID: 22391548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparin.
    Walterspiel JN; Feldman S; Van R; Ravis WR
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1875-8. PubMed ID: 1952861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aminoglycoside resistance in Gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg. Aminoglycoside Resistance Study Group.
    Vanhoof R; Nyssen HJ; Van Bossuyt E; Hannecart-Pokorni E
    J Antimicrob Chemother; 1999 Oct; 44(4):483-8. PubMed ID: 10588310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.